Silo Pharma rises on filing patent application for ketamine-based implant
18/03/2024 12:32
** Shares of drug developer Silo Pharma SILO.O rise 4.4%
to $1.92 premarket
** Co files U.S. patent application for its ketamine-based
implantable drug delivery system called SP-26
** SILO is developing SP-26 as a potential at-home pain
relief treatment for fibromyalgia, a chronic disorder that
causes pain and tenderness throughout the body and other chronic
pain conditions
** Up to last close, stock mostly flat in the last 12 months
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement